Immuron Ltd ADR - Asset Resilience Ratio
Immuron Ltd ADR (IMRN) has an Asset Resilience Ratio of 30.08% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Immuron Ltd ADR's Asset Resilience Ratio has changed over time. Check Immuron Ltd ADR PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Immuron Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Immuron Ltd ADR worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.04 Million | 30.08% |
| Total Liquid Assets | $3.04 Million | 30.08% |
Asset Resilience Insights
- Very High Liquidity: Immuron Ltd ADR maintains exceptional liquid asset reserves at 30.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immuron Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Immuron Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Immuron Ltd ADR (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Immuron Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 30.08% | $3.04 Million | $10.09 Million | -- |
| 2024-06-30 | 0.00% | $0.00 | $15.55 Million | -- |
| 2023-06-30 | 8.34% | $1.83 Million | $21.99 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $24.86 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $8.56 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $9.24 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $8.29 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $8.83 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $6.02 Million | -- |
| 2006-06-30 | 16.60% | $1.10 Million | $6.63 Million | -26.59pp |
| 2005-06-30 | 43.19% | $3.48 Million | $8.05 Million | +22.83pp |
| 2004-06-30 | 20.37% | $1.00 Million | $4.91 Million | -22.21pp |
| 2002-06-30 | 42.57% | $2.80 Million | $6.58 Million | -15.35pp |
| 2001-06-30 | 57.92% | $4.54 Million | $7.83 Million | -- |
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more